ESMO TAT 2021 | Safety of continued dosing of MEDI1191

Omid Hamid, MD, Cedars-Sinai Medical Center, Los Angeles, CA, discusses the safety of continued dosing of MEDI1191 (IL-12 mRNA) during the Phase I trial (NCT03946800), in which patients with solid tumors were intratumorally injected with MEDI1191 in combination with durvalumab. Intratumoral injection of MEDI1191 resulted in localized production of IL-12 in the tumor, stimulating immune cell and IFN gamma production, as well as inducing cytotoxic T cell activity into the tumor area. Despite some toxicity seen in continued dosing, early detection demonstrated the safety of MEDI1191. This interview took place during the ESMO TAT 2021 conference.